• Corpus ID: 78411461

Evidence-Based Series 2-18- EDUCATION AND INFORMATION 2014 A Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO The Use of FOLFIRINOX as First-Line Treatment for Metastatic Pancreatic Adenocarcinoma

@inproceedings{Hammad2014EvidenceBasedS2,
  title={Evidence-Based Series 2-18- EDUCATION AND INFORMATION 2014 A Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO The Use of FOLFIRINOX as First-Line Treatment for Metastatic Pancreatic Adenocarcinoma},
  author={Nazik Hammad and Roxanne Cosby and James Biagi and Malcolm W. Mackenzie},
  year={2014}
}
1 Citations

Tables from this paper

Minimally Invasive Total Gastrectomy

This chapter will discuss appropriate patient selection and learning curve of the procedure, the technique of laparoscopic gastrectomy with D2 lymphadenectomy, and considerations for postoperative management.

References

SHOWING 1-10 OF 11 REFERENCES

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

CONKO-008: Oxaliplatin (O)/folinic acid (FA)/5-fluorouracil (5-FU) (24 h) in combination with lapatinib as a second-line therapy in pancreatic cancer after gemcitabine failure: A phase I/II trial.

This trial aims to further improve therapeutic options for patients after Gemcitabine failure by combining OFF with lapatinib, a combined ErbB-1 and Erb B-2 tyrosine kinase inhibitor which showed preclinical synergy with 5-FU.

A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study

A multicenter phase III study to compare OFF and FF in pts with G refractory APC and the impact and the side effects of oxaliplatin is initiated.

Tumors of the Exocrine Pancreas

A mailing envelope structure and method wherein a single sheet is advantageously provided as a business form having a plurality of envelope blanks, each blank being equipped with perpendicular lines

Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study.

Between baseline and end of treatment, patients had improvement in all functional scales of the EORTC QLQ-C30, except cognitive functioning, and Responders had major improvement in global QOL.

The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation.

Attention to the barriers of guidelines development and the sociocultural nature of clinical practice, and respect for clinical experience, can lead to improved strategies for guidelines development.

Second-line chemotherapy with capecitabine (CAP) and oxaliplatin (OX) in patients with pancreatic or biliary tree adenocarcinoma (ADC).

After first-line treatment, CAPOX shows a tolerable toxicity and some activity and it can represent an alternative on selected pretreated pts, indicating that pancreatic and biliary tree ADC have unfavorable prognosis.

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

It is demonstrated that gemcitabine is more effective than 5-FU in alleviation of some disease-related symptoms in patients with advanced, symptomatic pancreas cancer and confers a modest survival advantage over treatment with5-FU.

Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial.

This triple combination combining all three classes of active cytotoxic drugs in APC is feasible and, by far, met the predefined efficacy criteria warranting further investigations.